Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cephalothin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 1.00 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 1.00 |
| ▸ | DNMT1 | P26358 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.84 |
| ▸ | MEN1 | O00255 | 2/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.84 |
| ▸ | GLA | P06280 | 1/20 | 0.84 |
| ▸ | APEX1 | P27695 | 1/20 | 0.84 |
| ▸ | PKM | P14618 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cephalothin SCHEMBL1624515 | 1.00 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL11039891 | 1.00 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL10974577 | 1.00 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL16072835 | 1.00 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL5791156 | 1.00 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL4394024 | 1.00 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL4319851 | 1.00 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL9159686 | 1.00 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL1331925 | 0.99 | MAPT (0.98) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL148784 | 0.99 | MAPT (0.98) | MAPTTDP1NR1I2HPGDCTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 26915 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637481-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-05-26 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| EP-4676500-A2 | MICROBIAL CONSORTIA | Kanvas Biosciences, Inc (US) | 2026-01-14 | — | — | EP | claimed |
| US-20250346910-A1 | METHODS AND COMPOSITIONS TO PREVENT MICROBIAL INFECTION | COMMENSE BIO INC (US) | 2025-11-13 | — | — | US | claimed |
| US-12465623-B2 | Use of parasites and extracellular vesicles obtained from parasites in cancer treatment | YEDITEPE UNIVERSITESI (TR) | 2025-11-11 | — | — | US | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-0004770-A2 | Pharmaceutical and dietary composition comprising gamma-linolenic acids | EFAMOL LIMITED (GB) | 1979-10-17 | — | — | EP | claimed |
| EP-0003407-A1 | Pharmaceutical and dietary composition comprising gamma-linolenic acids | EFAMOL LIMITED (GB) | 1979-08-08 | — | — | EP | claimed |
| US-4144391-A | REPLACING AN ACETOXY GROUP BY A SULFUR NUCLEOPHILE | ELI LILLY AND COMPANY (US) | 1979-03-13 | — | — | US | claimed |
| US-4143134-A | BACTERICIDES, ANTIBIOTIC POTENTIATORS | HOFFMANN-LA ROCHE INC. (US) | 1979-03-06 | — | — | US | claimed |
| US-4139702-A | Process for preparing cephalosporines | DOBFAR S.P.A. (IT) | 1979-02-13 | — | — | US | claimed |
| US-4100275-A | PEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 1978-07-11 | — | — | US | claimed |
| US-4028355-A | Cephalosporin purification process | SMITHKLINE CORPORATION (US) | 1977-06-07 | — | — | US | claimed |
| US-3984403-A | PAINLESS INTRAMUSCULAR INJECTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-10-05 | — | — | US | claimed |
| US-3937655-A | Method for preparing stable β-lactam-type-antibiotic susceptibility test discs | ELI LILLY AND COMPANY (US) | 1976-02-10 | — | — | US | claimed |
| US-3930949-A | Process for the production of 7-amino-Δ3 -cephem derivatives | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | claimed |